Exclusive insights content on every NHS system
- Easy-to-read ICS profiles and Investigations
- In-depth Briefings on the big picture trends shaping the landscape
- Benefit from over 50 data points that will help benefit your business case
Identify your best opportunities
- Create Watchlist Alerts to keep your team up to date with key partners and prospects
- See Investigations, Leadership, Documents, Spend and more for every system in one place
- Pinpoint opportunities and map your strategy with six powerful insight modules: National, Systems, Organisations, Leadership, Documents, and Spend
Download a sample HSJi Investigation
Using a mixture of proprietary intelligence, HSJ Intelligence brings you the top strategic issues facing specific providers and health systems.
Latest HSJi Review discusses restructuring neighbourhoods
Read Jack Serle's latest HSJi Review, which discusses how diagnostic performance in England is struggling with demand outstripping supply, even with the NHS’s laudable increases in capacity over the past five years. Read the full article here.
Latest Investigations
Surrey and Sussex Healthcare Trust
Patient flow is being impacted by sustained A&E demand, high bed occupancy, and particularly delayed discharges. The trust is increasing theatre and diagnostic capacity, while also planning reductions in both outsourcing and insourcing. However, the trust is currently running behind its financial plan and is struggling to reduce temporary staffing costs. As a result of these pressures, the trust could face cash flow problems later in the year.
AI in the NHS: Areas of adoption and barriers to progress
Adoption of AI tools and services in the NHS is accelerating, but unevenly. Diagnostics is the clinical service most impacted. Ambient voice technology will receive significant attention in 2026-27, with widespread adoption of AI in a range of administrative tasks, such as waiting list validation. Safety and governance are the most significant barriers to adoption.
Collaboration between pharma firms and the NHS: the state of play
Joint working between the NHS and the pharmaceutical industry is widespread. However, the NHS is often nervous about collaboration, fearing additional demands on stretched resources and criticism from those concerned that pharma companies will gain undue influence. Collaboration projects take many forms, but identifying undiagnosed patients and optimising treatment are the most common goals. The NHS usually wants pharma to provide funding, staff, and/or data analysis expertise. The government is focusing on increasing the number of commercial clinical trials carried out in the NHS.
Data points
The following data points were updated this week:
- Emergency care streaming indicator, Type 1 Departments - Major A&E %, Emergency care streaming indicator, Type 3 Departments - Other A&E/Minor Injury Unit, Four hours A&E performance (all patients), 12 hour A&E waits, 12 hour A&E waits (% of total attendances), A&E attendances, % beds occupied by delayed discharges, Discharge delays due to ‘internal’ reasons, Discharge delays due to ‘external’ reasons and Super stranded patients for Acute in November.
- Discharge delays due to ‘internal’ reasons and Discharge delays due to ‘external’ reasons for ICS in November.
- Number of cases waiting over one year and Proportion of cases waiting over one year % for Acute, community, and specialist in Oct.
- CQC Rating for Acute, SP, MH, Com, Amb in Q3 2025-26.
- Providers with 'outstanding' leadership and Year-plus waiters for ICS in Q3 2025-26.
- Elective patients waiting more than 18 weeks for Acute, Sp in Q3 2025-26.
- NHS talking therapies for MH in Q3 2025-26.
What our clients say
Trusted by
Find out more about how HSJ Intelligence can help you
Complete the form below and a member of the team will contact you.
HSJI Experts
With unrivalled access to senior figures, NHS data sources and rigorous primary research, HSJ experts have a unique insight on the NHS, and deep understanding of the strategic issues facing NHS organisations and leadership teams. HSJi offers exclusive, predictive analysis explaining key trends and the specific NHS organisations that are likely to be affected.
Alastair McLellan
Editor
Ben Clover
Bureau chief
Annabelle Collins
Senior correspondent
Matt Discombe
Correspondent
Oliver Hudson
Analyst
Nick Kituno
Correspondent
James Illman
Bureau chief
Alison Moore
Correspondent
Jack Serle
Senior insights correspondent
Dave West
Deputy editor
Collaboration between pharma firms and the NHS: the state of play
AI in the NHS: Areas of adoption and barriers to progress
The NHS in Wales: Autumn 2025 update